Michael B. Weiss is a member of Cahill Gordon & Reindel LLP’s intellectual property practice group with extensive experience practicing in the pharmaceuticals and biopharmaceutical industries, including molecular biology and related fields. He has also practiced in industries as varied as semiconductors, media and insurance.
Mr. Weiss counsels companies of all sizes and other owners of intellectual property with legal support designed to maximize the value of their patent, trademark, copyright, and trade secret holdings. He is notably experienced in intellectual property audits, and in negotiating and structuring major strategic collaborations, product acquisitions, software development agreements and licensing transactions. He provides due diligence support to companies engaged in mergers and acquisitions, joint ventures, and supporting public and private offerings of debt and equity securities, and has wide-ranging experience in co-development, co-promotion and related agreements across numerous disease and product areas.
Mr. Weiss also represents commercial and investment banks, private equity and venture capital firms in due diligence activities and in the structuring of transactions associated with the intellectual property-rooted aspects of mergers and acquisitions, joint ventures, and public and private offerings of debt and equity securities and asset acquisition financing.